Touchstone Investments Appoints Benjamin Alge as President
Alge succeeds E. Blake Moore Jr., slated to retire mid-year CINCINNATI–(BUSINESS WIRE)–Touchstone Investments (“Touchstone”), known for its Distinctively... Read more.
FDA Inspection Seminar: How to Prepare for and Survive an Inspection No Matter if You are a Class I, II, III Device, Pharmaceutical or Biologics Manufacturer (ON-DEMAND) – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “FDA Inspection” training has been added to ResearchAndMarkets.com’s offering. This seminar provides the... Read more.
Aya Locums’ Nurse Practitioner Named “2024 Locum Tenens Providers of the Year” by Locumpedia
SAN DIEGO–(BUSINESS WIRE)–#AyaLocums–Locumpedia named Emma Moore, Family Nurse Practitioner (NP) with Aya Locums, as a “2024 Locum Tenens Provider... Read more.
Fresh Faces Rx Elevates Patient Care with Perfect Corp.’s AI-Powered Skincare Pro Technology
AI-Driven Skin Analysis Enhances Consultations, Strengthens Patient Trust, and Delivers Measurable Results. NEW YORK–(BUSINESS WIRE)–Perfect Corp. (NYSE:... Read more.
Strategy Prices Perpetual Strife Preferred Stock Offering
TYSONS CORNER, Va.–(BUSINESS WIRE)–Strategy™ (Nasdaq: MSTR/STRK) (the “Company”) today announced the pricing of its offering on March 20, 2025... Read more.
Pega Announces Quarterly Cash Dividend for Second Quarter of 2025
WALTHAM, Mass.–(BUSINESS WIRE)–Pegasystems Inc. (NASDAQ: PEGA), The Enterprise Transformation Company™, today announced a quarterly cash dividend of... Read more.
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
NEW YORK–(BUSINESS WIRE)–OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate... Read more.
Global Hydrogen Market Report 2025-2035, with Profiles of Over 280 Companies Across the Hydrogen Value Chain – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Hydrogen Market 2025-2035” report has been added to ResearchAndMarkets.com’s offering. The global... Read more.
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS®... Read more.
Dentalcorp Reports Fourth Quarter and Full Year 2024 Results, Declares Inaugural Dividend
Revenue growth and margin expansion combine to drive robust Adjusted EBITDA and Adjusted Free Cash Flow per share growth Fourth Quarter 2024 Highlights Revenue of... Read more.